MedTrace Logo

Efficacy and Safety of Pregabalin Sustained Release Tablet for Postherpetic Neuralgia

NCT02868801 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 280

Last updated 2016-08-16

No results posted yet for this study

Summary

The purpose of this study is to evaluate the Efficacy and safety of pregabalin sustained release tablet versus placebo for postherpetic neuralgia.

Conditions

  • Postherpetic Neuralgia

Interventions

DRUG

Placebo

same intervention as the experimental group

DRUG

Pregabalin SR tablet 165mg/day

According to the efficacy and safety in titration

DRUG

Pregabalin SR tablet 330mg/day

According to the efficacy and safety in titration

DRUG

Pregabalin SR tablet 660mg/day

According to the efficacy and safety in titration.

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Lu Qianjin, M.D. · Second Xiangya Hospital of Central South University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2017-06-30
Completion
2017-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02868801 on ClinicalTrials.gov